EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Quantum BioPharma's Enterprise Value is $3.93 Mil.
Quantum BioPharma's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $-6.89 Mil. Therefore, Quantum BioPharma's EV-to-FCF for today is -0.57.
The historical rank and industry rank for Quantum BioPharma's EV-to-FCF or its related term are showing as below:
QNTM'
s EV-to-FCF Range Over the Past 10 Years
Min: -301.76 Med: -0.54 Max: 0.26
Current: -0.9
During the past 9 years, the highest EV-to-FCF of Quantum BioPharma was 0.26. The lowest was -301.76. And the median was -0.54.
QNTM's EV-to-FCF is ranked worse than 100% of 550
companies
in the Drug Manufacturers industry
Industry Median: 23.205
vs QNTM: -0.90
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
The historical data trend for Quantum BioPharma's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Quantum BioPharma's EV-to-FCF
For the Drug Manufacturers - Specialty & Generic subindustry, Quantum BioPharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Quantum BioPharma's EV-to-FCF Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Quantum BioPharma's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Quantum BioPharma's EV-to-FCF falls into.
Quantum BioPharma's current Enterprise Value is $3.93 Mil.
Quantum BioPharma's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.89 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Quantum BioPharma's PE Ratio (TTM) for today is calculated as:
Quantum BioPharma's share price for today is $5.66.
Quantum BioPharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-15.467.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Quantum BioPharma EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Quantum BioPharma's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
QNTM has been successfully added to your 